{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:25:27Z","timestamp":1789770327152,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10390022210022"],"award-info":[{"award-number":["10390022210022"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>During follow-up of glioblastoma patients after chemoradiation, expert teams often observe abnormalities on MRI with difficulty in distinguishing between tumor growth and pseudoprogression. Although advanced MRI techniques such as perfusion weighted imaging provide additional information, diagnostic uncertainty often remains, leading to incorrect or delayed diagnosis, and inappropriate treatment, such as unnecessary surgery. [<jats:sup>18<\/jats:sup>F]Fluoro-ethyl-tyrosine positron emission tomography (FET PET) has good discriminating power for this setting. Still, this diagnostic tool is not used frequently in The Netherlands due to costs, logistics and uncertainty about clinical benefit. In the FET POPPING study, we aim to determine the added value of [<jats:sup>18<\/jats:sup>F]FET PET for clinical management of glioblastoma patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A multicenter diagnostic randomized clinical trial will be performed, from August 2024 until December 2027. Adult patients (<jats:italic>n<\/jats:italic>=144) with isocitrate dehydrogenase (IDH)-wildtype glioblastoma will be included, who, at least \u22653 months after the concomitant phase of standard temozolomide-based chemoradiation, have new or increased contrast enhancement on MRI, causing doubt between tumor growth or pseudoprogression.<\/jats:p>\n            <jats:p>In this trial, pseudoprogression will be used as an encompassing term that includes radionecrosis and other treatment-related changes after (chemo-)radiotherapy. Included patients will be randomized 1:1 in two arms. The investigational arm receives an additional [<jats:sup>18<\/jats:sup>F]FET PET scan, and clinical management is based on the index MRI and [<jats:sup>18<\/jats:sup>F]FET PET together. Clinical management of the control arm is based on the index MRI alone. Exact clinical management, as based on the available imaging, is chosen at the discretion of the local multidisciplinary board. The primary study endpoints are (a) the percentage of patients undergoing unnecessary interventions and (b) health-related quality of life after 12 weeks. Secondary endpoints include time-to-diagnosis, overall survival, and cost-effectiveness.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>We hypothesize that the clinical management guided by an additional [<jats:sup>18<\/jats:sup>F]FET PET scan leads to fewer unnecessary interventions, better health-related quality of life after 12 weeks and among others reduced net healthcare costs, compared with management based on MRI only. <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>The trial is registered on ClinicalTrials.gov on the 24th of June 2024, with registration number NCT06480721.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13063-025-08921-8","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:00:48Z","timestamp":1750172448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["[18F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trial"],"prefix":"10.1186","volume":"26","author":[{"given":"V.J.","family":"Ruijters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.J.","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"van de Giessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Niers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.G.","family":"Broen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Anten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.E.M. Veldhuijzen","family":"van Zanten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.I.J.","family":"Arens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.H.A.","family":"Henssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Gijtenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.J.","family":"Sijben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ghariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.B.","family":"Bosma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.N.","family":"Stormezand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.W.J.","family":"Frederix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Dankbaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Robe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.C.","family":"Verhoeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.Y.F.L.","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.E.H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.T.","family":"ten Ham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Tolboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"issue":"5","key":"8921_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459\u201366.","journal-title":"Lancet Oncol"},{"issue":"23","key":"8921_CR2","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 2017;318(23):2306\u201316.","journal-title":"JAMA"},{"issue":"1","key":"8921_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-009-9809-4","volume":"94","author":"ER Gerstner","year":"2009","unstructured":"Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. 2009;94(1):97\u2013101.","journal-title":"J Neurooncol"},{"key":"8921_CR4","doi-asserted-by":"crossref","unstructured":"Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and pseudoresponse: Imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol. 2011;32(11):1978\u201385.","DOI":"10.3174\/ajnr.A2397"},{"key":"8921_CR5","doi-asserted-by":"crossref","unstructured":"Flies C, Becker A, van Hecke W, Kobalka P, Robe P, Snijders T, et al. PATH-06. Histopathological characteristics of treatment-induced effects versus progression in 180 re-resection samples from irradiated gliomas grade 2\u20134. Neuro Oncol. 2023;25(Suppl 5):v167-168.","DOI":"10.1093\/neuonc\/noad179.0636"},{"issue":"7","key":"8921_CR6","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2967\/jnumed.122.265149","volume":"64","author":"NJ Smith","year":"2023","unstructured":"Smith NJ, Deaton TK, Territo W, Graner B, Gauger A, Snyder SE, et al. Hybrid 18F-fluoroethyltyrosine PET and MRI with perfusion to distinguish disease progression from treatment-related change in malignant brain tumors: The quest to beat the toughest cases. J Nucl Med. 2023;64(7):1087\u201392.","journal-title":"J Nucl Med"},{"issue":"1","key":"8921_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pon.1929","volume":"21","author":"P Brocken","year":"2012","unstructured":"Brocken P, Prins JB, Dekhuijzen PN, van der Heijden HF. The faster the better?\u2014A systematic review on distress in the diagnostic phase of suspected cancer, and the influence of rapid diagnostic pathways. Psychooncology. 2012;21(1):1\u201310.","journal-title":"Psychooncology"},{"issue":"11","key":"8921_CR8","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1007\/s00259-004-1590-1","volume":"31","author":"G P\u00f6pperl","year":"2004","unstructured":"P\u00f6pperl G, G\u00f6tz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004;31(11):1464\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"8921_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00259-014-2959-4","volume":"42","author":"N Galldiks","year":"2015","unstructured":"Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2015;42(5):685\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"8921_CR10","first-page":"1293","volume":"17","author":"N Galldiks","year":"2015","unstructured":"Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, et al. The use of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol. 2015;17(9):1293\u2013300.","journal-title":"Neuro Oncol"},{"issue":"1","key":"8921_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-022-04201-6","volume":"161","author":"A Singnurkar","year":"2023","unstructured":"Singnurkar A, Poon R, Detsky J. 18F-FET-PET imaging in high-grade gliomas and brain metastases: A systematic review and meta-analysis. J Neurooncol. 2023;161(1):1\u201312.","journal-title":"J Neurooncol"},{"issue":"4","key":"8921_CR12","doi-asserted-by":"publisher","first-page":"498","DOI":"10.2967\/jnumed.119.233809","volume":"61","author":"PL de Zwart","year":"2020","unstructured":"de Zwart PL, van Dijken BRJ, Holtman GA, Stormezand GN, Dierckx R, van Laar PJ, et al. Diagnostic accuracy of PET tracers for the differentiation of tumor progression from treatment-related changes in high-grade glioma: A systematic review and meta-analysis. J Nucl Med. 2020;61(4):498\u2013504.","journal-title":"J Nucl Med"},{"issue":"9","key":"8921_CR13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/neuonc\/now058","volume":"18","author":"NL Albert","year":"2016","unstructured":"Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in neuro-oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18(9):1199\u2013208.","journal-title":"Neuro Oncol"},{"issue":"5","key":"8921_CR14","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3390\/diagnostics12051202","volume":"12","author":"T van de Weijer","year":"2022","unstructured":"van de Weijer T, Broen MPG, Moonen RPM, Hoeben A, Anten M, Hovinga K, et al. The use of 18F-FET-PET-MRI in neuro-oncology: The best of both worlds\u2014a narrative review. Diagnostics (Basel). 2022;12(5):1202.","journal-title":"Diagnostics (Basel)"},{"issue":"9","key":"8921_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/neuonc\/now310","volume":"19","author":"A Heinzel","year":"2017","unstructured":"Heinzel A, M\u00fcller D, Yekta-Michael SS, Ceccon G, Langen KJ, Mottaghy FM, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: An effectiveness and cost-effectiveness analysis. Neuro Oncol. 2017;19(9):1271\u20138.","journal-title":"Neuro Oncol"},{"issue":"6","key":"8921_CR16","doi-asserted-by":"publisher","first-page":"838","DOI":"10.2967\/jnumed.123.266687","volume":"65","author":"J Rosen","year":"2024","unstructured":"Rosen J, Werner JM, Ceccon GS, Rosen EK, Wollring MM, Stetter I, et al. MRI and 18F-FET PET for multimodal treatment monitoring in patients with brain metastases: A cost-effectiveness analysis. J Nucl Med. 2024;65(6):838\u201344.","journal-title":"J Nucl Med"},{"issue":"8","key":"8921_CR17","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"key":"8921_CR18","doi-asserted-by":"crossref","unstructured":"Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): A report of the RANO group. Lancet Oncol. 2024;25(1):8.","DOI":"10.1016\/S1470-2045(23)00525-9"},{"key":"8921_CR19","unstructured":"Richtlijnendatabase. Onderscheiden tumorprogressie en therapie-effect bij gliomen. 2020. Available from: https:\/\/richtlijnendatabase.nl\/richtlijn\/gliomen\/followup_na_gliomen\/onderscheiden_tumorprogressie_en_therapieeffect_bij_gliomen.html. Assessed 23 May 2024."},{"key":"8921_CR20","doi-asserted-by":"crossref","unstructured":"Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: Version 1.0. Eur J Nucl Med Mol Imaging. 2019;46(3):540\u201357.","DOI":"10.1007\/s00259-018-4207-9"},{"key":"8921_CR21","unstructured":"EORTC. EORTC QLQ-C30 scoring manual. Available from: https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf. Assessed 14 Aug 2024."},{"issue":"9","key":"8921_CR22","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1007\/s00520-014-2352-7","volume":"22","author":"R Chow","year":"2014","unstructured":"Chow R, Lao N, Popovic M, Chow E, Cella D, Beaumont J, et al. Comparison of the EORTC QLQ-BN20 and the FACT-Br quality of life questionnaires for patients with primary brain cancers: A literature review. Support Care Cancer. 2014;22(9):2593\u20138.","journal-title":"Support Care Cancer"},{"issue":"6","key":"8921_CR23","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ejca.2010.01.012","volume":"46","author":"MJ Taphoorn","year":"2010","unstructured":"Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46(6):1033\u201340.","journal-title":"Eur J Cancer"},{"key":"8921_CR24","unstructured":"EQ-5D. EQ-5D-5L user guide. 2019. Available from: https:\/\/euroqol.org\/wp-content\/uploads\/2023\/11\/EQ-5D-5LUserguide-23-07.pdf. Assessed 15 August 2024."},{"key":"8921_CR25","unstructured":"Zorginstituut Nederland. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg (versie 2024). 2024. Available from: https:\/\/www.zorginstituutnederland.nl\/over-ons\/publicaties\/publicatie\/2024\/01\/16\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg. Assessed 21 May 2024."},{"issue":"4","key":"8921_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","volume":"19","author":"MM Versteegh","year":"2016","unstructured":"Versteegh MM, Vermeulen KM, Evers SM, de Wit GA, Prenger R, Stolk EA. Dutch tariff for the five-level version of EQ-5D. Value Health. 2016;19(4):343\u201352.","journal-title":"Value Health"},{"key":"8921_CR27","unstructured":"iMTA. iMTA medical consumption questionnaire. Available from: https:\/\/www.imta.nl\/questionnaires\/imcq\/. Assessed 21 May 2024."},{"key":"8921_CR28","unstructured":"iMTA. iMTA productivity cost questionnaire. Available from: https:\/\/www.imta.nl\/questionnaires\/ipcq\/. Assessed 21 May 2024."},{"key":"8921_CR29","unstructured":"ZonMw. Budget impact analyses in de praktijk - leidraad en rekentool. 2020. Available from: https:\/\/www.zonmw.nl\/sites\/zonmw\/files\/typo3-migrated-files\/200205_BIA_Leidraad.pdf. Assessed 21 May 2024."},{"issue":"1","key":"8921_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12955-020-01628-1.PMID:33267842;PMCID:PMC7709349","volume":"18","author":"Y Pronk","year":"2020","unstructured":"Pronk Y, van der Weegen W, Vos R, Brinkman JM, van Heerwaarden RJ, Pilot P. What is the minimum response rate on patient-reported outcome measures needed to adequately evaluate total hip arthroplasties? Health Qual Life Outcomes. 2020;18(1):379. https:\/\/doi.org\/10.1186\/s12955-020-01628-1.PMID:33267842;PMCID:PMC7709349.","journal-title":"Health Qual Life Outcomes"},{"key":"8921_CR31","unstructured":"European Medicines Agency. Guideline on adjustment for baseline covariates in clinical trials. 2015. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-adjustment-baseline-covariates-clinical-trials_en.pdf. Assessed 21 May 2024."},{"key":"8921_CR32","unstructured":"NFU. Guideline quality assurance of research involving human subjects. 2020. Available from: https:\/\/www.nfu.nl\/sites\/default\/files\/2021-01\/21.00024_Guideline_Quality_assurance_of_research_involving_human_subjects_dec20_0.pdf. Assessed 21 May 2024."},{"key":"8921_CR33","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Quick Reference Guide. Version 5.0. Published November 27, 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Assessed 16 May 2025."},{"issue":"4","key":"8921_CR34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2967\/jnumed.121.262051","volume":"63","author":"C Brendle","year":"2022","unstructured":"Brendle C, Maier C, Bender B, Schittenhelm J, Paulsen F, Renovanz M, et al. Impact of 18F-FET PET\/MRI on clinical management of brain tumor patients. J Nucl Med. 2022;63(4):522\u20137.","journal-title":"J Nucl Med"},{"key":"8921_CR35","doi-asserted-by":"crossref","unstructured":"Koh ES, Gan HK, Senko C, Francis RJ, Ebert M, Lee ST, et al. [18F]-fluoroethyl-L-tyrosine (FET) in glioblastoma (FIG) TROG 18.06 study: Protocol for a prospective, multicentre PET\/CT trial. BMJ Open. 2023;13(8):1-11.","DOI":"10.1136\/bmjopen-2022-071327"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08921-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08921-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08921-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:00:51Z","timestamp":1750172451000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08921-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8921"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08921-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Research Ethics Committee \u201cNedMec\u201d on the 31 st of May 2024, with reference number NL86008.041.24, 24-091\/O. Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"This is not applicable, as no identifying information of the participants is presented here nor will it be included in the trial results reports.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"208"}}